324 related articles for article (PubMed ID: 34106558)
1. Systematic screening reveals synergistic interactions that overcome MAPK inhibitor resistance in cancer cells.
Yu Y; Tao M; Xu L; Cao L; Le B; An N; Dong J; Xu Y; Yang B; Li W; Liu B; Wu Q; Lu Y; Xie Z; Lian X
Cancer Biol Med; 2021 Jun; 19(2):229-52. PubMed ID: 34106558
[TBL] [Abstract][Full Text] [Related]
2. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in
Usta D; Sigaud R; Buhl JL; Selt F; Marquardt V; Pauck D; Jansen J; Pusch S; Ecker J; Hielscher T; Vollmer J; Sommerkamp AC; Rubner T; Hargrave D; van Tilburg CM; Pfister SM; Jones DTW; Remke M; Brummer T; Witt O; Milde T
Mol Cancer Ther; 2020 Aug; 19(8):1736-1750. PubMed ID: 32451331
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Inhibition of Kinase Pathways Overcomes Resistance of Colorectal Cancer Spheroids to Cyclic Targeted Therapies.
Thakuri PS; Gupta M; Joshi R; Singh S; Tavana H
ACS Pharmacol Transl Sci; 2019 Aug; 2(4):275-284. PubMed ID: 32259061
[TBL] [Abstract][Full Text] [Related]
4. Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors.
Sander CA; Rush EA; Shi J; Arantes LMRB; Tesi RJ; Ross MA; Calderon MJ; Watkins SC; Kirkwood JM; Ferris RL; Butterfield LH; Vujanovic L
J Transl Med; 2022 Jul; 20(1):331. PubMed ID: 35879777
[TBL] [Abstract][Full Text] [Related]
5. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of
Aloia A; Müllhaupt D; Chabbert CD; Eberhart T; Flückiger-Mangual S; Vukolic A; Eichhoff O; Irmisch A; Alexander LT; Scibona E; Frederick DT; Miao B; Tian T; Cheng C; Kwong LN; Wei Z; Sullivan RJ; Boland GM; Herlyn M; Flaherty KT; Zamboni N; Dummer R; Zhang G; Levesque MP; Krek W; Kovacs WJ
Clin Cancer Res; 2019 Nov; 25(22):6852-6867. PubMed ID: 31375515
[TBL] [Abstract][Full Text] [Related]
6. Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance.
Yang Z; Wang Y; Liu S; Deng W; Lomeli SH; Moriceau G; Wohlschlegel J; Piva M; Lo RS
Cancer Discov; 2022 Aug; 12(8):1942-1959. PubMed ID: 35638972
[TBL] [Abstract][Full Text] [Related]
7. Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes.
Terp MG; Gammelgaard OL; Vever H; Gjerstorff MF; Ditzel HJ
Mol Oncol; 2021 Dec; 15(12):3299-3316. PubMed ID: 34165921
[TBL] [Abstract][Full Text] [Related]
8. T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells.
Granados K; Hüser L; Federico A; Sachindra S; Wolff G; Hielscher T; Novak D; Madrigal-Gamboa V; Sun Q; Vierthaler M; Larribère L; Umansky V; Utikal J
Br J Cancer; 2020 Mar; 122(7):1023-1036. PubMed ID: 32063604
[TBL] [Abstract][Full Text] [Related]
9. Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.
Hong A; Moriceau G; Sun L; Lomeli S; Piva M; Damoiseaux R; Holmen SL; Sharpless NE; Hugo W; Lo RS
Cancer Discov; 2018 Jan; 8(1):74-93. PubMed ID: 28923912
[TBL] [Abstract][Full Text] [Related]
10. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF
Fu H; Cheng L; Sa R; Jin Y; Chen L
J Cell Mol Med; 2020 Mar; 24(6):3336-3345. PubMed ID: 31970877
[TBL] [Abstract][Full Text] [Related]
11. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.
Song C; Piva M; Sun L; Hong A; Moriceau G; Kong X; Zhang H; Lomeli S; Qian J; Yu CC; Damoiseaux R; Kelley MC; Dahlman KB; Scumpia PO; Sosman JA; Johnson DB; Ribas A; Hugo W; Lo RS
Cancer Discov; 2017 Nov; 7(11):1248-1265. PubMed ID: 28864476
[TBL] [Abstract][Full Text] [Related]
12. Notch signaling activation induces cell death in MAPKi-resistant melanoma cells.
Mikheil DM; Prabhakar K; Arshad A; Rodriguez CI; Newton MA; Setaluri V
Pigment Cell Melanoma Res; 2019 Jul; 32(4):528-539. PubMed ID: 30614626
[TBL] [Abstract][Full Text] [Related]
13. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.
Vashisht Gopal YN; Gammon S; Prasad R; Knighton B; Pisaneschi F; Roszik J; Feng N; Johnson S; Pramanik S; Sudderth J; Sui D; Hudgens C; Fischer GM; Deng W; Reuben A; Peng W; Wang J; McQuade JL; Tetzlaff MT; Di Francesco ME; Marszalek J; Piwnica-Worms D; DeBerardinis RJ; Davies MA
Clin Cancer Res; 2019 Nov; 25(21):6429-6442. PubMed ID: 31439581
[TBL] [Abstract][Full Text] [Related]
14. SOX10 deficiency-mediated LAMB3 upregulation determines the invasiveness of MAPKi-resistant melanoma.
Han S; Zhang M; Qu X; Wu Z; Huang Z; Hu Y; Li Y; Cui L; Si L; Liu J; Shao Y
Oncogene; 2024 Feb; 43(6):434-446. PubMed ID: 38102338
[TBL] [Abstract][Full Text] [Related]
15. Role of dual specificity phosphatases (DUSPs) in melanoma cellular plasticity and drug resistance.
Singh MK; Altameemi S; Lares M; Newton MA; Setaluri V
Sci Rep; 2022 Aug; 12(1):14395. PubMed ID: 35999349
[TBL] [Abstract][Full Text] [Related]
16. MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas.
Sigaud R; Albert TK; Hess C; Hielscher T; Winkler N; Kocher D; Walter C; Münter D; Selt F; Usta D; Ecker J; Brentrup A; Hasselblatt M; Thomas C; Varghese J; Capper D; Thomale UW; Hernáiz Driever P; Simon M; Horn S; Herz NA; Koch A; Sahm F; Hamelmann S; Faria-Andrade A; Jabado N; Schuhmann MU; Schouten-van Meeteren AYN; Hoving E; Brummer T; van Tilburg CM; Pfister SM; Witt O; Jones DTW; Kerl K; Milde T
Nat Commun; 2023 Jul; 14(1):4533. PubMed ID: 37500667
[TBL] [Abstract][Full Text] [Related]
17. Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling Axis.
Vanneste M; Feddersen CR; Varzavand A; Zhu EY; Foley T; Zhao L; Holt KH; Milhem M; Piper R; Stipp CS; Dupuy AJ; Henry MD
Front Oncol; 2020; 10():442. PubMed ID: 32346533
[TBL] [Abstract][Full Text] [Related]
18. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
Zhang G; Frederick DT; Wu L; Wei Z; Krepler C; Srinivasan S; Chae YC; Xu X; Choi H; Dimwamwa E; Ope O; Shannan B; Basu D; Zhang D; Guha M; Xiao M; Randell S; Sproesser K; Xu W; Liu J; Karakousis GC; Schuchter LM; Gangadhar TC; Amaravadi RK; Gu M; Xu C; Ghosh A; Xu W; Tian T; Zhang J; Zha S; Liu Q; Brafford P; Weeraratna A; Davies MA; Wargo JA; Avadhani NG; Lu Y; Mills GB; Altieri DC; Flaherty KT; Herlyn M
J Clin Invest; 2016 May; 126(5):1834-56. PubMed ID: 27043285
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma.
Ferretti LP; Böhi F; Leslie Pedrioli DM; Cheng PF; Ferrari E; Baumgaertner P; Alvarado-Diaz A; Sella F; Cereghetti A; Turko P; Wright RH; De Bock K; Speiser DE; Ferrari R; Levesque MP; Hottiger MO
Cancer Res; 2023 Dec; 83(23):3974-3988. PubMed ID: 37729428
[TBL] [Abstract][Full Text] [Related]
20. Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia.
Fang K; Sun M; Leng Z; Chu Y; Zhao Z; Li Z; Zhang Y; Xu A; Zhang Z; Zhang L; Chen T; Xu M
J Exp Clin Cancer Res; 2023 Mar; 42(1):73. PubMed ID: 36978187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
